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A B S T R A C T
Background: Vaccination against rotavirus has shown great potential
for reducing the primary cause of severe childhood gastroenteritis.
Previous economic evaluations of rotavirus vaccination in France
have not modeled the potential impact of vaccines on disease burden
via reduced transmission. Objective: To determine the cost-
effectiveness of the introduction of pentavalent rotavirus vaccination
into the French infant vaccination schedule. Methods: We developed
an age-structured model of rotavirus transmission calibrated to 6
years of French gastroenteritis incidence and vaccine clinical trial
data. We evaluated the cost-effectiveness of pentavalent rotavirus
vaccination considering that 75% of infants would receive the three-
dose vaccine course. Results: Our model predicts that rotavirus
vaccination will decrease rotavirus gastroenteritis incidence and
associated clinical outcomes in vaccinated and unvaccinated individ-
uals, delay the seasonal peak of infection, and increase the age of
infection. From the societal perspective, our base-case scenario
predicts that vaccination coverage would be cost-effective at €115
or €135 per vaccine course at €28,500 and €39,500/quality-adjusted
life-year (QALY) gained, respectively, and suggests that almost 95% of
the ﬁnancial beneﬁts will be recouped within the ﬁrst 5 years
following vaccination implementation. From the third-party payer
perspective, incremental cost-effectiveness ratios ranged from €12,500
to €20,000/QALY, respectively. Our uncertainty analysis suggests that
ﬁndings were sensitive to various assumptions including the number
of hospitalizations, outpatient visits, and the extent of QALY losses
per rotavirus episode. Conclusions: Introducing pentavalent rotavirus
vaccination into the French infant vaccination schedule would sig-
niﬁcantly reduce the burden of rotavirus disease in children, and
could be cost-effective under plausible conditions.
Keywords: cost-effectiveness of rotavirus, herd immunity, rotavirus
model, rotavirus vaccination.
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Introduction
Rotavirus infection, the primary cause of gastroenteritis in
children worldwide, carries a signiﬁcant disease burden [1]. In
the absence of oral rehydration therapy, rotavirus gastroenteritis
(RVGE) can cause rapid dehydration, which may lead to death [2].
In developed countries, rotavirus infection is associated with low
mortality, but is responsible for high morbidity. France faces a
signiﬁcant societal and economic burden due to rotavirus infec-
tion, with 19,200 hospitalizations and 131,200 ambulatory visits
annually due to RVGE among children younger than 5 years [3].
Rotavirus vaccines have been introduced into infant vaccina-
tion schedules in several developed countries since their licens-
ing in 2006, including the United Kingdom and Germany. In
France, the Haut Conseil de Santé Publique recently published
its recommendation for the implementation of national rotavirus
vaccination for infants younger than 6 months [4]. Data from
Australia [5], the United States [6–8], Belgium [9], and Israel [10]
suggest that vaccination is highly effective in decreasing RVGE.
Moreover, in countries where universal vaccination has been
introduced, a 20% reduction in RVGE cases has been observed
among unvaccinated children [11]. These reports indicate that
there is a substantial RVGE case reduction due to both direct and
indirect effects of vaccination. However, none of the previous
studies assessing the cost-effectiveness of rotavirus vaccination
in France [3,12–15] has modeled the effect of herd protection.
We developed a dynamic model of rotavirus transmission in
France to evaluate the population-level impact of introducing uni-
versal pentavalent vaccination into the infant vaccination schedule
in France. Using the predictions from the dynamic model, we
evaluated the cost-effectiveness of pentavalent rotavirus vaccination
from the third-party payer (TPP) and societal perspectives. This study
could help to inform policy decisions in predicting the outcomes of a
universal pentavalent rotavirus vaccination program in France.
Methods
Dynamic Model
We developed an epidemiological population-based model of
rotavirus transmission in France (detailed in the supporting
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information). The dynamic model structure (Fig. 1) takes into
account that the risk of infection depends on both the number of
previous infections [16] and the age at exposure [17]. The model
includes 19 age groups: 0 to 2, 2 to 4, 4 to 6, 6 to 12, … , 22 to 24
months and 2 to 3, 3 to 4, 4 to 5, 5 to 25, 25 to 45, 45 to 65, older
than 65 years, and distinguishes between primary, secondary,
and subsequent infections. Infection may be either asympto-
matic or symptomatic with either mild or moderate-to-severe
RVGE [16]. Following infection, we assume there is temporary
complete immunity [18] that lasts for an average of 18 and 24
months following ﬁrst and second infections, respectively [19,20].
The infectiousness of an infected individual is based on the viral
shedding of the infected individual [21]. The extent of viral
shedding depends on both the immunity of the infected individ-
ual that has been built up from previous exposures and on the
severity of the disease. In our sensitivity analysis, we considered
three additional waning scenarios (from 6 months to 3 years)
(Table 1). Contact rates between age groups were parameterized
using age-stratiﬁed European physical contact data [22]. We
assumed that a vaccine dose is either effective or not effective,
and that each effective vaccine dose confers the same protection
as a single natural infection. We estimated the per-dose vaccine
efﬁcacy by calibrating the dynamic model to the pentavalent
vaccine efﬁcacy data from the 2-year clinical trial [23], assuming a
given duration of temporary immunity following each dose.
These trials showed that vaccinated individuals have their risk
of any RVGE reduced by 68% and their risk of moderate-to-severe
RVGE reduced by 86.7%.
To estimate empirically unknown epidemiological parameters
(Table 1), we calibrated our model to weekly national acute
gastroenteritis incidence from 2008 to 2013 in France. These data
were collected from the French Sentinels network, detailing the
incidence of acute diarrhea stratiﬁed by yearly age groups [24].
We converted these incidences to RVGE by considering the
proportion of those with acute gastroenteritis who test positive
for rotavirus each month [24–30] to capture the seasonal pattern
of rotavirus in France. For individuals younger than 5 years, we
scaled the age-speciﬁc incidences of RVGE with the following age
groups: 0 to 6 months, 6 to 12 months, 1 to 2 years, 2 to 3 years,
and 3 to 5 years to ensure that the age distribution among RVGE
infected will match that in previous RVGE studies in France
[26,27,29]. Given that not all cases are reported, we scaled the
incidence by a ﬁxed factor such that the overall mean annual
number of RVGE in children younger than 5 years will be 296,500,
as suggested by the High Council for Public Health in France [3].
To estimate the RVGE infection for individuals older than 5
years, we used prospective data from the Netherlands that
estimate that the age-speciﬁc proportion of gastroenteritis cases
attributable to rotavirus for individuals aged 5 years and older lies
between 1.5% and 3.3% [31,32]. Given that the reported rates of
RVGE in France are similar to the ones observed in the Nether-
lands (see, e.g., [29]), we assumed the same proportion of RVGE
for those with gastroenteritis episode as the ones observed in
those prospective studies [31,32]. This assumption leads to
around 27.5% of all RVGE cases in France in individuals 5 years
and older. Overall, our approach ensures that for our model
calibration, the data used will capture the actual seasonal
patterns, RVGE age distribution, and the total number of cases
(both reported and unreported) in France.
Clinical Outcomes
The epidemiological results generated by the dynamic model were
integrated into an economic evaluation to estimate the cost-
effectiveness of pentavalent rotavirus vaccination introduction
into the French infant vaccination schedule. For the economic
evaluation, we considered four clinical outcomes: 1) general
practitioner (GP) visit, 2) hospitalization (due to a community or
a nosocomial infection), 3) emergency department (ED) visit, and 4)
death. A proportion of severe RVGE cases were assumed to be
hospitalized, attend the ED, or die. A proportion of any (severe or
mild) RVGE cases were assumed to require a GP visit. Speciﬁcally,
in the absence of vaccination, we assumed that among individuals
with severe RVGE infection, 19,200 will be hospitalized, 5,460 will
attend the ED, and 13 will die annually [26,33]. Among individuals
with any RVGE, 131,200 will visit the GP (Table 3) [26,33]. Clinical
trials suggest that a full three-dose course of pentavalent vacci-
nation prevents 95.6% of hospitalizations, 93.8% of ED visits, and
87.2% of GP visits in vaccinated individuals [34]. We combined both
these clinical trial data with model predictions to estimate the
proportion of clinical outcomes averted because of both direct and
indirect effects (see Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2016.05.011).
In our univariate sensitivity analysis, we included the risk of
intussusception consistent with a recent US study that found
that within a birth cohort of 4.3 million infants vaccine-
associated intussusception could cause an excess 0.2 (range 0.1–
0.3) deaths, 45 (range 21–86) hospitalizations, and 13 (range 6–25)
cases managed in short-stay or ED settings [35].
Quality of Life
In the base-case analysis, we considered a loss of 0.003274 and
0.001715 quality-adjusted life- years (QALYs) per severe and mild
RVGE episode for a child, respectively. This is based on the
observation that each RVGE episode lasts for 5.4 and 6.5 days,
with a daily utility of 0.816 and 0.884 for a mild case and a severe
case, respectively [36,37], consistent with previous French eco-
nomic analyses [13,36,37]. In the sensitivity analysis, we varied
the QALY loss by 20%. On the basis of previous studies that
showed substantial parental QALY losses due to an RVGE infec-
tion of their child [38,39], and in line with previous cost-effective
studies on rotavirus in France and elsewhere [14,40–42], we also
considered the same QALY loss for one caregiver in our base-case
scenario.
Fig. 1 – State diagram of epidemiologic model, with arrows
corresponding to possible transition between states as a
result of infection, recovery, or immunity waning.
Individuals are born with temporary maternal immunity
(state M). This immunity wanes and individuals move to the
susceptible state (S1). Infections can be asymptomatic (IA1),
mild RVGE (IM1), or severe RVGE (IS1). Individuals recover
from infection to become temporarily immune (R1). This
immunity wanes to allow repeat infections with either a
secondary infection or a subsequent infection. Each effective
vaccine dose confers protection equivalent to natural
infection. RVGE, rotavirus gastroenteritis.
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Costs
Consistent with other studies, we conservatively only included
the costs and beneﬁts attributable to children younger than 5
years because the vast majority of reported rotavirus cases occur
in children younger than 5 years, and there is much uncertainty
about the clinical burden and severity of RVGE in older children
and adults [29,33,42,43]. Costs were compiled from available
published sources in France and were inﬂated to 2015 euros
[44,45] (Table 2). For comparison with other studies, we present
cost-effectiveness results for two representative vaccine course
prices of €115, corresponding to the lowest ofﬁcial price available
for the pentavalent rotavirus vaccine in the European private
market, and €135, corresponding to the current out-of-pocket
advised price of RotaTeq in the French private market. Given that
the rotavirus vaccine would be administered concomitantly with
other childhood vaccines as part of the existing French vaccina-
tion schedule, or during a routine ambulatory visit, no cost of
vaccine administration was considered [3,13]. However, because
1% of vaccinated infants may be brought back for a follow-up visit
to their GP, attributable to the rotavirus vaccine, we increased the
cost of each vaccine course by 1% of a GP visit to reﬂect this
extra cost.
Economic Analysis
To allow comparison with standard measures of cost-effect-
iveness in France, the results are presented in cost per QALY
gained from introducing the pentavalent rotavirus vaccine into
the infant schedule assuming 75% vaccine uptake [13] in
Table 1 – Epidemiological parameter values and distributions where applicable.
Parameter Symbol Base-case value Distribution (range)
used in uncertainty
(sensitivity) analysis
Source
Initial population size (millions) N 65.63 [1]
Birth rate (annual per 1000 individuals) f 12.8 [1]
Probability of severity given infection d [2,3]
Asymptotic Mild Severe
Primary infection 0.53 0.34 0.13
Secondary infection 0.75 0.22 0.03
Subsequent infection r65 y 0.8 0.2 0
Subsequent infection 465 y 0.4 0.3 0.3 Estimated
Duration of infection (d) 1/γ [3,4]
First infection 7
Second/subsequent/asymptomatic
infection
3.5
Relative infectiousness ρ RVGE [2,3]
Asymptotic Mild Severe
First infection 0.1 1 1
Second/subsequent infection 0.1 0.5 0.8
Relative susceptibility following: σ [3,4]
Primary infection 0.62 Uniform (0.56–0.68)
Second/subsequent infection 0.37 Uniform (0.34–0.4)
Seasonal offset (radians) θ 1.355 Estimated
Seasonal amplitude A 0.0685 Estimated
Alternative waning
scenarios
Duration of immunity (mo) 1/ω A B C
Maternal antibodies 3 3 3 3
First infection 18 4 9 27
Second/subsequent infection 24 6 12 37
Susceptibility rate for age range (probability
of infection per infectious contact)
b A B C Estimated
0–6 mo 0.283 0.275 0.278 0.286
6–24 mo 0.52 0.489 0.497 0.525
24–60 mo 0.13 0.096 0.109 0.146
5–65 y 0.01 0.009 0.009 0.009
465 y 0.02 0.017 0.017 0.017
Per-dose vaccine efﬁcacy r 0.35 Baseline: Uniform (0.31–
0.39)
Estimated
A: Uniform (0.38–0.43)
B: Uniform (0.34–0.38)
C: Uniform (0.3–0.35)
Vaccination coverage ϕ 0.75 [5]
The distributions were sampled during the global uncertainty analysis. Ranges are given when the parameter is varied in the univariate/
multivariate sensitivity analysis.
Severity of infection is deﬁned by physicians on the basis of a 20-point scoring system [6], with 10 as threshold between mild and severe
infections.
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comparison to the status quo of no national vaccination. The
analysis was performed in accordance with Haute Autorité de
Santé guidelines [46]. We evaluated the cost-effectiveness of
rotavirus vaccination from two perspectives: 1) the TPP perspec-
tive: quantifying all direct medical costs, 65% of vaccine purchase
payable by the national health insurance, and quality of life lost
because of RVGE for those younger than 5 years and one care-
giver, and 2) the societal perspective (referred to as the “collec-
tive” perspective in Haute Autorité de Santé guidelines), which
includes all direct costs due to RVGE episodes, all vaccine
purchase costs, and quality of life lost due to RVGE for those
younger than 5 years and one caregiver. Conservatively, we did
not incorporate losses of productivity [47,48].
The discounted costs and beneﬁts of a rotavirus vaccination
program were evaluated over a time horizon of 50 years. Con-
sistent with the guidelines, all costs and QALYs were discounted
at a rate of 4% annually for the ﬁrst 30 years, decreasing linearly
to 2% annually by 50 years [46].
We performed univariate sensitivity analyses on the following
parameters: 1) QALY losses due to RVGE and the number of
caregivers, 2) vaccination coverage, 3) clinical outcome costs,
4) waning rate of the vaccine, and 5) discount rate. With respect
to discounting, as most cost-effectiveness analysis guidelines
suggest, we considered in our base case equal discounting for
cost and effects [49]. Nevertheless, given that cost and effects
need to be depending on distinct quantities such as the growth
rates of national income and healthy life expectancy, lowering
the discount rate for effects relative to that of costs is recom-
mended [49]. Accordingly, in our sensitivity analysis, we con-
ducted a differential discounting by ﬁxing the costs to 4% and
varied the effects between 2% and 4%. Additional sensitivity
analyses were performed on the probabilities of the respective
clinical outcomes. A probabilistic global uncertainty analysis was
also conducted to incorporate empirical uncertainty in epidemio-
logical, costs, and vaccine-related parameter values (Table 1).
Results
Dynamic Model
Analysis of our base-case scenario predicts that the introduction
of rotavirus vaccination in France will decrease RVGE incidence
and the requirement for clinical outcomes in both vaccinated and
unvaccinated individuals. The mean reduction in children
younger than 5 years ranges from 62% to 65% (2 years after
vaccine introduction) to 71% to 75% (10 years after vaccine
introduction), depending on the clinical outcome (Table 3).
Our model predicts a delay in peak incidence of around 1
month relative to no vaccination (Fig. 2A,B). The median age of
infection for children younger than 5 years is expected to
increase by 2 months after 3 years of vaccination. Because of
Table 2 – Cost-effectiveness parameter values and distributions where applicable.
Parameter Base-case
value
Distribution (range) used in global
uncertainty (univariate/
multivariate sensitivity) analysis
Source
Annual incidence rate of symptomatic
RVGE in children o5 y before
vaccination (per 1000 individuals)
Uniform (0.8–1.2) [7]
Ofﬁce visits 31.4
ED visits 1.3
Hospitalization 4.6
Nosocomial infection 2.89
Deaths 0.0031
Discount rate 4% for the ﬁrst 30
y and linearly
decreasing to
2% after 50 y
Costs (adjusted to €2013) Perspective Total costs  gamma (11.36, 0.098) [8,9]; Supplemental Materials
found at http://dx.doi.org/
10.1016/j.jval.2016.05.011
TPP SP
GP consultations 36.64 67.5
ED visits 86.2 142.2
Hospitalizations/deaths 1331.5 1385.5
Nosocomial infections 1178.6 1503.8
Other direct costs (travel
costs, extra diapers, childcare)
0 16
Vaccination follow-ups 0.37 0.68
Mortality [10]
A life expectancy
of 1; 20; 41.3
minus
patient’s age
with
probability of
1/3 each
The distributions were sampled during the global uncertainty analysis. Ranges are given when the parameter was varied in the univariate/
multivariate sensitivity analysis.
ED, emergency department; GP, general practitioner; SP, societal perspective; TPP, third-party payer.
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reduced transmission, our model predicts up to 60.5% reduction
in infection among the unvaccinated elderly in the long-term
following vaccine introduction.
Cost-Effectiveness
From the societal perspective, our base-case analysis predicts
that the incremental cost-effectiveness ratios (ICERs) are €28,500
and €39,500/QALY gained for per-course vaccine prices of €115
and €135, respectively (Table 4). From the TPP perspective, where
the government covers 65% of the vaccine price, the ICER drops to
€12,500 and €20,000/QALY gained for €115 and €135 per vaccine
course, respectively (Table 4). If transmission dynamics are
neglected, our static model suggests that the cost per QALY
may increase by up to 19% from the societal perspective when
considering a vaccine course price of €115.
Table 3 – Estimated mean annual number of infected among children o5 y and demand for medical outcomes
following vaccination predicted from the base-case parameter values.
Annual no. of clinical
outcomes
Mild
RVGE
Severe
RVGE
GP
visits
ED
visits
Nosocomial
infection
Hospital
visits
Deaths
No vaccination 142,834 153,665 131,200 5,460 9,913 19,200 13
Average at 2 y 54,315 56,677 48,105 1,924 3,460 6,702 5
Average at 5 y 41,229 42,340 35,821 1,401 2,507 4,855 4
Average at 10 y 40,963 42,048 35,571 1,391 2,487 4,817 4
ED, emergency department; RVGE, rotavirus gastroenteritis.
Fig. 2 – Base-case predictions following vaccination. (A) Projected weekly number of RVGE cases. Rapid decline is projected by
2 years postvaccination. (B) Comparison of prevalence given years postvaccination, characterized by a delay in the peak of
infection. (C) Age distribution among individuals with RVGE postvaccination is characterized by an increase in the age of
infection. (D) Average reduction varies across different clinical outcomes, and gradually plateaus following 5 years
postvaccination. ED, emergency department; GP, general practitioner; RVGE, rotavirus gastroenteritis.
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Univariate sensitivity analyses indicate that the ICERs are
sensitive to the effect of the epidemiological, quality-of-life, and
cost assumptions (Fig. 3). The most inﬂuential parameter is the
QALY consideration for caregivers. For example, assuming no
QALY losses for a caregiver would elevate the ICER to €51,000/
QALY from the societal perspective.
Our analysis predicts that the ICER is highly sensitive to the
incidence of nosocomial rotavirus infections. For example,
assuming 4,460 annual cases of nosocomial infection, which is
consistent with the lowest limit from a previous epidemiological
study [4], the ICER can increase to €35,000/QALY. In contrast,
with 14,370 nosocomial infection episodes, which is in the
range of previous estimates [4], the ICER drops to €23,500/QALY
gained.
Given the uncertainty surrounding the duration of immunity
conferred from natural infection and vaccination, we also cali-
brated our model to alternative waning rates from 6 months to 3
years, compared with 2 years in the base case. The ICER was
robust under changes to plausible variation in waning protection
rates (Fig. 3). Results were also robust across the discount rate
and vaccine coverage. The QALY losses had a small-to-moderate
impact on the ICER. For example, when using a discount rate of
2.5% as recently recommended in France [50], the ICER is
estimated at €28,000/QALY from the societal perspective.
Accounting for possible intussusception due to vaccination had
a minimal impact, with an increase in the ICER for €50/QALY
gained at most.
To quantify the certainty and robustness of our results to
policymakers, we conducted a global probabilistic uncertainty
analysis (Table 1). At a vaccine course price of €115, the proba-
bility of national rotavirus vaccination being cost-effective is 99%
and 99.9% from the societal perspective and the TPP perspective,
respectively, for a threshold of €50,000/QALY. For a price of €135,
the cost-effective probabilities remained high at 88% and 99.9%,
respectively (Fig. 4).
We conducted a budget impact analysis to determine how
quickly the vaccine costs to the TPP and the society, respectively,
are recouped as a result of the decrease in RVGE clinical out-
comes–related costs. We found that at a vaccine course price of
€115, 65% and 52% of the vaccine costs are predicted to be
recouped. Given that rotavirus is primarily a childhood disease,
the time to reach this payback is relatively short, with almost 95%
of the overall gain being recouped within the ﬁrst 5 years (Fig. 5).
Discussion
We developed a dynamic population-based model of rotavirus
transmission to determine both the effectiveness and the cost-
effectiveness of introducing pentavalent rotavirus vaccination
into the national infant immunization schedule of France. Our
study is the ﬁrst to integrate a dynamic model of rotavirus
transmission with a cost-effectiveness analysis of rotavirus
vaccination in France. Our approach makes it possible to account
Table 4 – Results of cost-effectiveness analyses.
Discounted costs (€2013 million) No vaccination Dynamic model Static model
Third-party payer
GP consultations 132.5 42.0 45.7
ED visits 14.0 3.7 4.1
Hospitalizations 757.1 188.7 214.0
Nosocomial infections 346.0 86.2 98.0
Deaths 0.51 0.15 0.18
Home care treatment 0.0 0.0 0.0
Total costs (excluding vaccine course) 1250 320.7 361.9
Vaccine course costs to the third-party payer* (€115  65%) 0.0 1,335 1,335
Vaccine course costs to the third-party payer* (€13565%) 0.0 1,566 1,566
Cost-effectiveness (ICER, €/QALY)
€115 per vaccine course 12,500 16,000
€135 per vaccine course 20,000 24,000
Societal perspective
GP consultations 244.1 77.4 84.3
ED visits 23.0 6.0 6.8
Hospitalizations 787.6 196.3 222.5
Nosocomial infections 441.5 110.0 124.7
Deaths 0.58 0.17 0.2
Home care treatment 51.6 16.0 16.4
Total costs (excluding vaccine course costs) 1548.4 405.9 454.9
Vaccine course† (€115) 2,056 2,056
Vaccine course (€135) 2,410 2,410
Total discounted QALYs 46,478 14,163 18,153
Cost-effectiveness (ICER, €/QALY)
€115 per vaccine course 28,500 34,000
€135 per vaccine course 39,500 46,500
Threshold cost-effective price (€)
Willingness-to-pay threshold of 30,000 €/QALY 118 108
Willingness-to-pay threshold of 50,000 €/QALY 154 140
ED, emergency department; GP, general practitioner; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
* Includes 65% coverage of the cost of vaccine course, and the costs of the third-party payer for GP follow-up visit in 1% of the vaccinated.
† Includes costs of vaccinations and GP follow-up visit in 1% of the vaccinated.
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for indirect protection through herd immunity and therefore to
assess both the epidemiological and economic impacts of a
national vaccination program.
Our epidemiological model replicates several trends that have
been observed following universal vaccination implementation in
other countries. For example, in line with observations in several
countries following the implementation of universal rotavirus
vaccination program [8,51,52], the epidemiological model compo-
nent of our analysis predicts that RVGE infection in unvaccinated
elderly is reduced substantially, a beneﬁt conservatively not
considered in our cost-effectiveness analysis. Consistent also
with previous observations [9,53], our model predicts that vacci-
nation would delay the peak RVGE incidence by 1 month. In
France, the current RVGE peak overlaps with that of other
gastroenteritis and respiratory infections in February and early
March [25]. Thus, both preventing and delaying RVGE cases may
ease the seasonal pressure on hospitals when high occupancy is
expected by reducing the demand for hospital beds, reducing the
cost of medical personnel overtime, as well as preventing
nosocomial infections due to overcrowding [54].
We integrate the uncertainty surrounding key epidemiological
and vaccine parameters into our predictions by using Monte-
Carlo sampling and explain the resulting implications for the
impact of vaccination. In particular, to incorporate the high
Fig. 3 – Univariate sensitivity analysis of the ICER assuming vaccine course price of €115 in (A) and (B) from the perspective of
the third-party payer, and (C) and (D) from the society perspective. ED, emergency department; GP, general practitioner; ICER,
incremental cost-effectiveness ratio; QALY, quality-adjusted life-year.
Fig. 4 – Global uncertainty analysis results. Threshold curves
showing the effect of vaccine course price on the probability
that rotavirus vaccination is cost-effective in France from the
social perspective and the third-party payer perspective at
prices of €115 and €135 per course, respectively. DALY,
disability-adjusted life-year; ICER, incremental cost-
effectiveness ratio.
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uncertainty with respect to the annual number of clinical out-
comes before vaccination, we used uniform (i.e., naive) distribu-
tions. The most inﬂuential parameters are the consideration of
caregivers’ quality of life and the incidence of nosocomial
infections and hospitalizations. Nevertheless, with the exception
of the scenario removing QALY losses for a caregiver entirely, all
univariate sensitivity analyses for €115 led to ICERs below
€50,000/QALY. Thus, the probabilistic analysis conﬁrms the
robustness of our ﬁndings.
As for any model, there are inevitably simpliﬁcations in the
model structure as well as uncertainty regarding parameteriza-
tion from empirical data. Given that not all individuals seek
medical treatment and some are misdiagnosed, the total RVGE
incidence is not known. We assumed the same RVGE cases and
likelihood of clinical outcomes as provided in previous studies
[4,13]. In line with other dynamic models of rotavirus infection
[43], the model assumes temporary and complete immunity
following infection. However, the duration of this temporary
immunity remains uncertain. We assumed that vaccine-
induced protection wanes in the same way as naturally induced
protection. For consistency, we also used the same assumptions
for quality-of-life parameters as previous cost-effectiveness stud-
ies conducted in France [3,13]. However, cost-utility analyses are
inherently limited when evaluating childhood diseases because it
is extremely difﬁcult to accurately assess quality of life in
children. RVGE also impacts the quality of life of parents [37].
In this context, consideration of the burden to the caregiver is
pertinent, and should be taken into account when evaluating the
economic value of childhood diseases.
Two previous cost-effectiveness analyses conducted for
France [3,13,15] suggested higher ICERs than did this study. The
discrepancy stems from three important differences: 1) lack of
incorporation of herd protection in previous models (leading to a
reduction in ICER by 17%–19%), 2) differences in health outcome
costs and vaccine prices, and 3) the extent of nosocomial
infections considered. For example, one of the previous studies
[13] did not consider nosocomial infections and focused on
children younger than 3 years, whereas another previous study
[15] accounted for the lower bound of reported nosocomial
infections [4]. However, rotavirus vaccination was observed to
reduce nosocomial infection by 72% in less than 4 years following
vaccination of 72% to 88% of toddlers in Austria and thus should
not be neglected or underestimated.
Consistent with other cost-effectiveness studies of rotavirus
vaccination, we conservatively only included in our base case the
costs and beneﬁts attributable to children younger than 5 years
because the vast majority of reported rotavirus cases, and in
particular RVGE-related hospitalizations, occur in children
younger than 5 years [29,33,42,43]. Nevertheless, in countries
where rotavirus vaccination has been introduced into the infant
immunization schedule, a signiﬁcant reduction in RVGE has been
observed even among unvaccinated adults [8]. There is limited
available data on the extent of RVGE burden in adults in France or
in other developed countries. As data become available, future
studies should conduct cost-effectiveness analysis that will
incorporate the entire population. Nevertheless, even in our
analysis when we considered individuals younger than 5 years
only, when herd protection is neglected, our static model pre-
dicted a 19% increase in the cost per QALY gained. This difference
indicates that herd protection even among those younger than 5
years plays a crucial role in determining the cost-effectiveness of
universal rotavirus vaccination program.
Conservatively, we did not incorporate the indirect costs of
productivity losses for a caregiver in addition to QALYs losses, both
of which could be considered in a full societal perspective. Indeed,
RotaTeq clinical trials demonstrated an efﬁcacy of 87% in reducing
the number of workdays missed by parents to care for their
children [55]. This economic burden of productivity loss can
contribute to almost 50% of the total cost of RVGE in France.
Similarly, the beneﬁts of rotavirus vaccination on the health care
system, such as hospital capacity, were not evaluated in the model
because these beneﬁts are difﬁcult to quantify monetarily [56].
Therefore, extending our conservative analysis to account for the
full economic and societal beneﬁts could further improve the cost-
effectiveness proﬁle of pentavalent rotavirus vaccination in France.
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